Gout Clinical Trial
— GOUTOfficial title:
Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit in Urate Lowering Therapy Initiators
| Verified date | April 2022 |
| Source | Lille Catholic University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The objective of this research is to evaluate the correlation between DECT and US explorations performed in a routine clinical setting for the measurement of change in tophus size in gout patients after 24 months of treatment.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | November 8, 2021 |
| Est. primary completion date | November 8, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - diagnosis of gout based on the ACR/EULAR 2015 criteria - uricemia =6 mg/dL - warranted introduction of urate-lowering therapy according to the ACR 2012 or EULAR 2016 criteria - signature of the informed consent - social insurance affiliation Exclusion Criteria: - pregnancy or breastfeeding - patient under legal guardianship |
| Country | Name | City | State |
|---|---|---|---|
| France | Hospital Group of the Catholic Institute | Lomme | |
| France | Bichat Hospital | Paris | |
| France | Lariboisière Hospital | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Lille Catholic University | Horizon Pharma Rheumatology LLC |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Correlation between US and DECT measurement of change in tophus volume | Spearman rank correlation between the change in tophus volume after 24 months of treatment measured by ultrasonography or by DECT. | after 24 months of treatment | |
| Secondary | Correlation between US and DECT measurement of change in tophus volume | Spearman rank correlation between the change in tophus volume after 6, 12 and 24 months of treatment measured by ultrasonography or by DECT. | after 6 months, 12 months and 24 months of treatment | |
| Secondary | Change of DECT urate score | Change from baseline after 6, 12 and 24 months of treatment in DECT urate score | after 6 months, 12 months and 24 months of treatment | |
| Secondary | Link between the change of DECT urate score and the persistence of the double contour sign | During ultrasonography, a double contour of the articulation can be visible. This outcome will compare the change in the DECT urate score between the patients for who the double contour stay visible and those for who it disapear.
This outcome register if this double contour stay visible. |
after 6 months, 12 months and 24 months of treatment | |
| Secondary | Correlation between the change of DECT urate score and the change in serum uric acid levels | The Spearman correlation between the change from baseline of the DECT urate score and the serum uric acid levels will be computed for each time point. | after 6 months, 12 months and 24 months of treatment | |
| Secondary | Correlation between the change of DECT urate score and the number of gout attacks | The Spearman correlation between the change from baseline of the DECT urate score and the number of gout attack will be computed. | after 6 months, 12 months and 24 months of treatment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04060173 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
|
Phase 1 | |
| Not yet recruiting |
NCT06187519 -
UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
|
N/A | |
| Completed |
NCT03635957 -
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
|
Phase 4 | |
| Completed |
NCT04966325 -
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
|
Early Phase 1 | |
| Completed |
NCT03015948 -
A Single Dose Study of SHR4640 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT02855437 -
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
|
N/A | |
| Active, not recruiting |
NCT02702375 -
Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases
|
N/A | |
| Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
| Completed |
NCT00995618 -
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
|
Phase 2 | |
| Completed |
NCT00985127 -
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
|
Phase 2 | |
| Terminated |
NCT04987294 -
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT03291782 -
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT03388515 -
A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.
|
Phase 1 | |
| Completed |
NCT06189404 -
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
|
Phase 1 | |
| Enrolling by invitation |
NCT03336203 -
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
|
Phase 4 | |
| Recruiting |
NCT05586958 -
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
|
Phase 3 | |
| Recruiting |
NCT04047394 -
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05507723 -
Tight Control of Gouty Arthritis Compared to Usual Care
|
N/A | |
| Recruiting |
NCT06056570 -
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
|
Phase 1/Phase 2 | |
| Completed |
NCT02557126 -
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
|
Phase 2 |